Jazz Pharmaceuticals, Inc. (JAZZ)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 2,890
- Market Cap
- $16.2B
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
SentiSense also tracks daily options readings for Jazz Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Jazz Pharmaceuticals, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.